Beat-to-beat blood pressure variability and Alzheimer’s disease pathophysiology

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Introduction

Elevated blood pressure variability (BPV) is predictive of Alzheimer’s disease neuropathologic change observed with AD biomarkers. However, prior studies have largely focused on visit-to-visit BPV, which may be influenced by antihypertensive medication adherence and other external factors. Few studies have investigated beat-to-beat BPV, a reliable and direct measure of cardiovascular and autonomic function relevant to AD.

Methods

Independently living older adults (N=132) were recruited from the community. Participants underwent continuous blood pressure monitoring and venipuncture. Plasma p- Tau 217 , p-Tau 181 , GFAP, NfL, and amyloid-β 42/40 ratio were assessed. Linear regression examined the relationship between beat-to-beat systolic BPV and plasma AD biomarkers with and without adjustment for age, sex, systolic blood pressure, and apolipoprotein E4 ( APOE4 ) carrier status.

Results

Elevated beat-to-beat BPV was associated with elevated plasma p-Tau 217 (β=0.32, p=0.008), plasma p-Tau 181 (β=0.22, p=0.05), and plasma GFAP (β=0.41, p=0.00001). Elevated BPV was not associated with plasma amyloid-β 42/40 ratio or plasma NfL.

Discussion

Increased beat-to-beat BPV is associated with increased Core 1 T 1 biomarkers of phosphorylated and secreted AD tau in blood plasma (i.e., pTau 217 , pTau 181 ), but not with amyloid-β 42/40 ratio, a biomarker more exclusively indexing cerebral amyloid retention alone.

Elevated BPV was also associated with higher plasma GFAP, a marker of astrocyte reactivity. These findings are consistent with prior studies relating visit-to-visit BPV to AD biomarkers, suggesting that intrinsic cardiovascular and/or autonomic factors underlie links between BPV and AD.

Article activity feed

  1. Beat-to-beat blood pressure variability and Alzheimers disease pathophysiology #NeuroDegeneration 🧪🧠 https://www.medrxiv.org/content/10.64898/2026.11.10.26367476v1